Current Investigator-Led Research

1. The feasibility of introducing a harmonised treatment regimen, comparing affordable blood tests and PET CT scans, to improve two year survival rates in children, adolescents and young adults with Hodgkin lymphoma in South Africa. SACCSG HL-2018 National PI: Prof Jennifer Geel, University of the Witwatersrand

2. An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667). ClinicalTrials.gov Identifier: NCT03407144 Prof Geel is the national principal investigator (PI) for this trial. [Link]

3. Treating malignant extracranial germ cell tumours in South Africa. SACCSG MECGCT-2018 National PI: Prof Marc Hendricks, University of Cape Town

4. National Retinoblastoma Treatment Protocol National PI: Prof Mariana Kruger, University of Stellenbosch

5. Evaluation of CHOC Volunteer Programme at Charlotte Maxeke Johannesburg Academic Hospital PI: Mrs Jillian Graham, CHOC Volunteer Coordinator

6. Delay in Diagnosis in Paediatric Oncology during the SARS-CoV 2 Pandemic at Charlotte Maxeke Johannesburg Academic Hospital”. PI: Ms Rumaanah Osman, GEMP III student, University of the Witwatersrand

7. The Spectrum of Paediatric Chronic Kidney Disease in Johannesburg PI: Ms Hayley Wright, GEMP III student, University of the Witwatersrand

8. SIOP global mapping programme – palliative care PI: Ms Khumo Myezo

9. SIOP Global mapping of African paediatric oncology resources PI: Prof Jennifer Geel

10. Inherited cancer predisposing mutations in a cohort of childhood cancer patients PI: Prof Amanda Krause

International Clinical Trials

1. An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667). ClinicalTrials.gov Identifier: NCT03407144 Prof Geel is the national principal investigator (PI) for this trial.

2. A Study of Lenvatinib (MK-7902) in Pediatric Participants with Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) (E7080-G000-231) ClinicalTrials.gov Identifier: NCT04447755

We work with Wits Clinical Research and their experienced staff on these clinical trials.

If you would like to chat to us about feasibility for a paediatric study at Charlotte Maxeke Johannesburg Academic Hospital, please use the contact form to get in touch.